132 related articles for article (PubMed ID: 21311578)
1. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.
Cohen CR; Brown J; Moscicki AB; Bukusi EA; Paull JR; Price CF; Shiboski S
PLoS One; 2011 Jan; 6(1):e16258. PubMed ID: 21311578
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
4. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.
Moscicki AB; Kaul R; Ma Y; Scott ME; Daud II; Bukusi EA; Shiboski S; Rebbapragada A; Huibner S; Cohen CR
J Acquir Immune Defic Syndr; 2012 Feb; 59(2):134-40. PubMed ID: 22067666
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.
Chen MY; Millwood IY; Wand H; Poynten M; Law M; Kaldor JM; Wesselingh S; Price CF; Clark LJ; Paull JR; Fairley CK
J Acquir Immune Defic Syndr; 2009 Apr; 50(4):375-80. PubMed ID: 19214122
[TBL] [Abstract][Full Text] [Related]
6. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
Price CF; Tyssen D; Sonza S; Davie A; Evans S; Lewis GR; Xia S; Spelman T; Hodsman P; Moench TR; Humberstone A; Paull JR; Tachedjian G
PLoS One; 2011; 6(9):e24095. PubMed ID: 21935377
[TBL] [Abstract][Full Text] [Related]
7. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
Chavoustie SE; Carter BA; Waldbaum AS; Donders GGG; Peters KH; Schwebke JR; Paull JRA; Price CF; Castellarnau A; McCloud P; Kinghorn GR
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():13-18. PubMed ID: 31812702
[TBL] [Abstract][Full Text] [Related]
8. "Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.
Carballo-Diéguez A; Giguere R; Dolezal C; Chen BA; Kahn J; Zimet G; Mabragaña M; Leu CS; McGowan I
AIDS Behav; 2012 Oct; 16(7):1761-74. PubMed ID: 21863338
[TBL] [Abstract][Full Text] [Related]
9. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
Bakobaki JM; Lacey CJ; Bukenya MI; Nunn AJ; McCormack S; Byaruhanga RN; Okong P; Namukwaya SW; Grosskurth H; Whitworth JA
AIDS; 2005 Dec; 19(18):2149-56. PubMed ID: 16284465
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis.
Hemmerling A; Harrison W; Schroeder A; Park J; Korn A; Shiboski S; Cohen CR
Sex Transm Dis; 2009 Sep; 36(9):564-9. PubMed ID: 19543144
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
[TBL] [Abstract][Full Text] [Related]
13. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.
Rupp R; Rosenthal SL; Stanberry LR
Int J Nanomedicine; 2007; 2(4):561-6. PubMed ID: 18203424
[TBL] [Abstract][Full Text] [Related]
14. Antibiotics for induction and maintenance of remission in Crohn's disease.
Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
[TBL] [Abstract][Full Text] [Related]
15. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.
Patton DL; Cosgrove Sweeney YT; McCarthy TD; Hillier SL
Antimicrob Agents Chemother; 2006 May; 50(5):1696-700. PubMed ID: 16641437
[TBL] [Abstract][Full Text] [Related]
16. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.
Waldbaum AS; Schwebke JR; Paull JRA; Price CF; Edmondson SR; Castellarnau A; McCloud P; Kinghorn GR
PLoS One; 2020; 15(5):e0232394. PubMed ID: 32365097
[TBL] [Abstract][Full Text] [Related]
17. EVO100 prevents chlamydia and gonorrhea in women at high risk of infection.
Chappell BT; Mena LA; Maximos B; Mollan S; Culwell K; Howard B
Am J Obstet Gynecol; 2021 Aug; 225(2):162.e1-162.e14. PubMed ID: 33705748
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
[TBL] [Abstract][Full Text] [Related]
19. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z;
AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
